Tags

Type your tag names separated by a space and hit enter

Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta.
Life Sci. 2008 Jun 06; 82(23-24):1142-53.LS

Abstract

Diallylsulfide (DAS), an antioxidant and anti-inflammatory agent was evaluated for its ability to repress lung fibrosis induced by bleomycin in Wistar rats. A single intra tracheal administration of bleomycin (6.5 U/kg BW) was administered to pulmonary fibrosis group, while DAS (120 mg/kg BW) was administered intraperitoneally throughout the experimental period. Fibrotic changes in the lungs were estimated by measuring lung hydroxyproline content. Bleomycin administration significantly (P<0.05) reduced the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) in the lung tissues. Bleomycin caused a significant decrease in the level of reduced glutathione (GSH), which was accompanied with significant increase in lipid peroxidation (LPO) level, and myeloperoxidase (MPO) activity, in the lung tissues. An increase in the level of cell counts in bronchoalveolar lavage fluid (BALF) was observed in bleomycin induced group. DAS administration altered the levels of enzymic antioxidants, TBARS, MPO and GSH towards normal values. Histopathological analysis and picrosirius red staining showed an increased collagen deposition in rats receiving bleomycin alone that was decreased upon DAS treatment. Immunohistochemical studies revealed that DAS reduced the bleomycin-induced activation of inducible nitric oxide synthase (iNOS) and nuclear factor kappa-B (NF-kappaB) and decreased the augmented levels of the early inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), in the lung tissues. The present study provides evidence that DAS might serve as a novel target for the therapeutic treatment of lung fibrosis.

Authors+Show Affiliations

Department of Biochemistry, University of Madras, Guindy campus, Chennai, 600 025, Tamil nadu, India.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18462759

Citation

Kalayarasan, Srinivasan, et al. "Diallyl Sulfide Attenuates Bleomycin-induced Pulmonary Fibrosis: Critical Role of iNOS, NF-kappaB, TNF-alpha and IL-1beta." Life Sciences, vol. 82, no. 23-24, 2008, pp. 1142-53.
Kalayarasan S, Sriram N, Sudhandiran G. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. Life Sci. 2008;82(23-24):1142-53.
Kalayarasan, S., Sriram, N., & Sudhandiran, G. (2008). Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. Life Sciences, 82(23-24), 1142-53. https://doi.org/10.1016/j.lfs.2008.03.018
Kalayarasan S, Sriram N, Sudhandiran G. Diallyl Sulfide Attenuates Bleomycin-induced Pulmonary Fibrosis: Critical Role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. Life Sci. 2008 Jun 6;82(23-24):1142-53. PubMed PMID: 18462759.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. AU - Kalayarasan,Srinivasan, AU - Sriram,Narayanan, AU - Sudhandiran,Ganapasam, Y1 - 2008/04/04/ PY - 2007/09/14/received PY - 2008/02/27/revised PY - 2008/03/18/accepted PY - 2008/5/9/pubmed PY - 2008/7/22/medline PY - 2008/5/9/entrez SP - 1142 EP - 53 JF - Life sciences JO - Life Sci VL - 82 IS - 23-24 N2 - Diallylsulfide (DAS), an antioxidant and anti-inflammatory agent was evaluated for its ability to repress lung fibrosis induced by bleomycin in Wistar rats. A single intra tracheal administration of bleomycin (6.5 U/kg BW) was administered to pulmonary fibrosis group, while DAS (120 mg/kg BW) was administered intraperitoneally throughout the experimental period. Fibrotic changes in the lungs were estimated by measuring lung hydroxyproline content. Bleomycin administration significantly (P<0.05) reduced the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) in the lung tissues. Bleomycin caused a significant decrease in the level of reduced glutathione (GSH), which was accompanied with significant increase in lipid peroxidation (LPO) level, and myeloperoxidase (MPO) activity, in the lung tissues. An increase in the level of cell counts in bronchoalveolar lavage fluid (BALF) was observed in bleomycin induced group. DAS administration altered the levels of enzymic antioxidants, TBARS, MPO and GSH towards normal values. Histopathological analysis and picrosirius red staining showed an increased collagen deposition in rats receiving bleomycin alone that was decreased upon DAS treatment. Immunohistochemical studies revealed that DAS reduced the bleomycin-induced activation of inducible nitric oxide synthase (iNOS) and nuclear factor kappa-B (NF-kappaB) and decreased the augmented levels of the early inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), in the lung tissues. The present study provides evidence that DAS might serve as a novel target for the therapeutic treatment of lung fibrosis. SN - 0024-3205 UR - https://www.unboundmedicine.com/medline/citation/18462759/Diallyl_sulfide_attenuates_bleomycin_induced_pulmonary_fibrosis:_critical_role_of_iNOS_NF_kappaB_TNF_alpha_and_IL_1beta_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0024-3205(08)00131-8 DB - PRIME DP - Unbound Medicine ER -